These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 33815053)

  • 1. Drug Repurposing for Parkinson's Disease: The International Linked Clinical Trials experience.
    Stott SRW; Wyse RK; Brundin P
    Front Neurosci; 2021; 15():653377. PubMed ID: 33815053
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Twelve Years of Drug Prioritization to Help Accelerate Disease Modification Trials in Parkinson's Disease: The International Linked Clinical Trials Initiative.
    Wyse RK; Isaacs T; Barker RA; Cookson MR; Dawson TM; Devos D; Dexter DT; Duffen J; Federoff H; Fiske B; Foltynie T; Fox S; Greenamyre JT; Kieburtz K; Kordower JH; Krainc D; Matthews H; Moore DJ; Mursaleen L; Schwarzschild MA; Stott SRW; Sulzer D; Svenningsson P; Tanner CM; Carroll C; Simon DK; Brundin P
    J Parkinsons Dis; 2024; 14(4):657-666. PubMed ID: 38578902
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recent Advances in Drug Repurposing for Parkinson's Disease.
    Chen X; Gumina G; Virga KG
    Curr Med Chem; 2019; 26(28):5340-5362. PubMed ID: 30027839
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Parkinson's Disease Drug Therapies in the Clinical Trial Pipeline: 2022 Update.
    McFarthing K; Rafaloff G; Baptista M; Mursaleen L; Fuest R; Wyse RK; Stott SRW
    J Parkinsons Dis; 2022; 12(4):1073-1082. PubMed ID: 35527571
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Linked Clinical Trials initiative (LCT) for Parkinson's disease.
    Brundin P; Wyse RK
    Eur J Neurosci; 2019 Feb; 49(3):307-315. PubMed ID: 30269406
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Approaches to Disease Modification for Parkinson's Disease: Clinical Trials and Lessons Learned.
    Hung AY; Schwarzschild MA
    Neurotherapeutics; 2020 Oct; 17(4):1393-1405. PubMed ID: 33205384
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tetracycline repurposing in neurodegeneration: focus on Parkinson's disease.
    Bortolanza M; Nascimento GC; Socias SB; Ploper D; Chehín RN; Raisman-Vozari R; Del-Bel E
    J Neural Transm (Vienna); 2018 Oct; 125(10):1403-1415. PubMed ID: 30109452
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Linked clinical trials--the development of new clinical learning studies in Parkinson's disease using screening of multiple prospective new treatments.
    Brundin P; Barker RA; Conn PJ; Dawson TM; Kieburtz K; Lees AJ; Schwarzschild MA; Tanner CM; Isaacs T; Duffen J; Matthews H; Wyse RK
    J Parkinsons Dis; 2013 Jan; 3(3):231-9. PubMed ID: 24018336
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Parkinson's Disease Drug Development Since 1999: A Story of Repurposing and Relative Success.
    Boucherie DM; Duarte GS; Machado T; Faustino PR; Sampaio C; Rascol O; Ferreira JJ
    J Parkinsons Dis; 2021; 11(2):421-429. PubMed ID: 33459662
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Parkinson's Disease Drug Therapies in the Clinical Trial Pipeline: 2020.
    McFarthing K; Buff S; Rafaloff G; Dominey T; Wyse RK; Stott SRW
    J Parkinsons Dis; 2020; 10(3):757-774. PubMed ID: 32741777
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The NINDS Parkinson's disease biomarkers program.
    Rosenthal LS; Drake D; Alcalay RN; Babcock D; Bowman FD; Chen-Plotkin A; Dawson TM; Dewey RB; German DC; Huang X; Landin B; McAuliffe M; Petyuk VA; Scherzer CR; Hillaire-Clarke CS; Sieber BA; Sutherland M; Tarn C; West A; Vaillancourt D; Zhang J; Gwinn K;
    Mov Disord; 2016 Jun; 31(6):915-23. PubMed ID: 26442452
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emulated Clinical Trials from Longitudinal Real-World Data Efficiently Identify Candidates for Neurological Disease Modification: Examples from Parkinson's Disease.
    Laifenfeld D; Yanover C; Ozery-Flato M; Shaham O; Rosen-Zvi M; Lev N; Goldschmidt Y; Grossman I
    Front Pharmacol; 2021; 12():631584. PubMed ID: 33967767
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Repurposing of Copper(II)-chelating Drugs for the Treatment of Neurodegenerative Diseases.
    Lanza V; Milardi D; Di Natale G; Pappalardo G
    Curr Med Chem; 2018 Feb; 25(4):525-539. PubMed ID: 28521682
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Parkinson's Disease Drug Therapies in the Clinical Trial Pipeline: 2021 Update.
    McFarthing K; Rafaloff G; Baptista MAS; Wyse RK; Stott SRW
    J Parkinsons Dis; 2021; 11(3):891-903. PubMed ID: 34151864
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Hypoxia Response Pathway: A Potential Intervention Target in Parkinson's Disease?
    Janssen Daalen JM; Koopman WJH; Saris CGJ; Meinders MJ; Thijssen DHJ; Bloem BR
    Mov Disord; 2024 Feb; 39(2):273-293. PubMed ID: 38140810
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DNL151, DNL201, and BIIB094: experimental agents for the treatment of Parkinson's disease.
    Müller T
    Expert Opin Investig Drugs; 2023; 32(9):787-792. PubMed ID: 37755071
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Repurposing anti-diabetic drugs for the treatment of Parkinson's disease: Rationale and clinical experience.
    Foltynie T; Athauda D
    Prog Brain Res; 2020; 252():493-523. PubMed ID: 32247373
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genome-wide Association Identifies Novel Etiological Insights Associated with Parkinson's Disease in African and African Admixed Populations.
    Rizig M; Bandres-Ciga S; Makarious MB; Ojo O; Crea PW; Abiodun O; Levine KS; Abubakar S; Achoru C; Vitale D; Adeniji O; Agabi O; Koretsky MJ; Agulanna U; Hall DA; Akinyemi R; Xie T; Ali M; Shamim EA; Ani-Osheku I; Padmanaban M; Arigbodi O; Standaert DG; Bello A; Dean M; Erameh C; Elsayed I; Farombi T; Okunoye O; Fawale M; Billingsley KJ; Imarhiagbe F; Jerez PA; Iwuozo E; Baker B; Komolafe M; Malik L; Nwani P; Daida K; Nwazor E; Miano-Burkhardt A; Nyandaiti Y; Fang ZH; Obiabo Y; Kluss JH; Odeniyi O; Hernandez D; Odiase F; Tayebi N; Ojini F; Sidranksy E; Onwuegbuzie G; D'Souza AM; Osaigbovo G; Berhe B; Osemwegie N; Reed X; Oshinaike O; Leonard H; Otubogun F; Alvarado CX; Oyakhire S; Ozomma S; Samuel S; Taiwo F; Wahab K; Zubair Y; Iwaki H; Kim JJ; Morris HR; Hardy J; Nalls M; Heilbron K; Norcliffe-Kaufmann L; ; Blauwendraat C; Houlden H; Singleton A; Okubadejo N
    medRxiv; 2023 May; ():. PubMed ID: 37398408
    [TBL] [Abstract][Full Text] [Related]  

  • 19. How should we be using biomarkers in trials of disease modification in Parkinson's disease?
    Vijiaratnam N; Foltynie T
    Brain; 2023 Dec; 146(12):4845-4869. PubMed ID: 37536279
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson's disease dementia and cognitive impairment in Parkinson's disease.
    Rolinski M; Fox C; Maidment I; McShane R
    Cochrane Database Syst Rev; 2012 Mar; 2012(3):CD006504. PubMed ID: 22419314
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.